BioLineRx Ltd. Announces Positive Topline Results for BL-1020, a First in Class GABA Enhanced Antipsychotic for the Treatment of Schizophrenia
JERUSALEM, Israel, Sept. 14, 2009 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today topline results from its phase 2b EAGLE (Effective Antipsychosis via GABA Level Enhancement) study assessing the efficacy, safety and tolerability of BL-1020, conducted under a US FDA IND (Investigational New Drug).